Polaris AI Pharma announced on the 2nd that it has successfully completed the "2024 Smart Eco-Factory Construction Project" led by the Korea Environment Corporation under the Ministry of Environment.
The Smart Eco-Factory Construction Project is a government-led initiative aimed at transforming factories into eco-friendly facilities by supporting small and medium-sized enterprises in reducing greenhouse gases and pollutants, and improving energy and resource efficiency. Since signing the agreement in June last year, Polaris AI Pharma has established eco-friendly infrastructure within its factory through equipment improvements and system implementation.
Through this project, the company introduced energy-saving equipment such as high-efficiency boilers, temperature and humidity control air conditioners, and inverter pumps, and applied solar power generation systems, factory energy management systems (FEMS), and monitoring systems (ICT) to drastically reduce energy consumption. This resulted in reduced greenhouse gas emissions and lowered factory operating costs.
In particular, the project exceeded its targets by achieving annual reductions of 250 tCO2eq in carbon emissions, 320 tons in water pollution, and 0.73 tons in waste, as well as generating approximately 150 million KRW in economic benefits.
Kim Young-kwan, CEO of Polaris AI Pharma, stated, "Through the establishment of this smart eco-factory, we have laid the foundation for sustainable eco-friendly management," adding, "We will continue to expand energy-saving measures and the adoption of eco-friendly processes to strengthen ESG (Environmental, Social, and Corporate Governance) management."
He also mentioned, "We will strive to enhance corporate value through the development of AI models specialized in the pharmaceutical domain."
Meanwhile, Polaris AI Pharma was incorporated into the Polaris Office Group in March last year and changed its name to reflect its future-oriented business vision. The company plans to increase R&D efficiency by integrating AI technology into the development process of active pharmaceutical ingredients, aiming to reduce costs and accelerate generic drug development.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
